FORMAMIDE MONOMERS AND POLYMERS SYNTHESIZED THEREFROM

    公开(公告)号:US20200290949A1

    公开(公告)日:2020-09-17

    申请号:US16815772

    申请日:2020-03-11

    摘要: Formamide group-containing monomers and polymers made by polymerizing the monomers are provided. Also provided are methods of polymerizing the monomers and methods of synthesizing functionalized polymers by pre- and/or post-polymerization functionalization. The monomers are non-toxic and can generate highly reactive isocyanate and isonitrile precursors in a one-pot synthesis that enables the incorporation of complex functionalities into the side-chain of the polymers that are synthesized from the monomers.

    Catecholamine derivatives for obesity and neurological disorders
    9.
    发明授权
    Catecholamine derivatives for obesity and neurological disorders 有权
    儿茶酚胺衍生物用于肥胖和神经障碍

    公开(公告)号:US09266817B2

    公开(公告)日:2016-02-23

    申请号:US14336911

    申请日:2014-07-21

    申请人: EMORY UNIVERSITY

    发明人: Keqiang Ye

    摘要: Novel compounds, compositions, and methods related to the activation of the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of a compound containing a catecholamine backbone and pharmaceutically acceptable salts, prodrugs, and derivatives thereof. Specifically, methods, compositions, and compounds for the treatment of disorders including neurological disorders, neuropsychiatric disorders, and metabolic disorders are provided. For example, a first method is provided of treating or reducing the risk of depression, anxiety, or obesity in a subject, which includes administering to the subject a therapeutically effective amount of the described compounds. A further method of promoting neuroprotection in a subject also is provided, which includes administering to the subject a therapeutically effective amount of the described compounds.

    摘要翻译: 提供了与TrkB受体活化相关的新型化合物,组合物和方法。 所述方法包括在体内或体外施用治疗有效量的含有儿茶酚胺骨架的化合物及其药学上可接受的盐,前药和衍生物。 具体地,提供了用于治疗包括神经障碍,神经精神障碍和代谢紊乱的疾病的方法,组合物和化合物。 例如,提供了治疗或降低受试者的抑郁,焦虑或肥胖的风险的第一种方法,其包括向受试者施用治疗有效量的所述化合物。 还提供了在受试者中促进神经保护作用的另一种方法,其包括向受试者施用治疗有效量的所述化合物。